Darwin Biosciences
Developer of a point-of-care, self-contained diagnostic platform that uses saliva sampling and a host-response biomarker panel to detect acute-phase infections. The platform integrates sample processing, heating, and nucleic-acid amplification to generate rapid results at or near the point of care. The organization reports clinical development activity, field use during COVID-19, and positions the technology for applications including early sepsis detection and other pathogen-agnostic diagnostics.
Industries
Nr. of Employees
small (1-50)
Products
Point-of-care saliva-based diagnostic platform
A self-contained diagnostic device that accepts saliva samples, performs automated sample processing and nucleic-acid amplification, and displays results at the point of care.
Point-of-care saliva-based diagnostic platform
A self-contained diagnostic device that accepts saliva samples, performs automated sample processing and nucleic-acid amplification, and displays results at the point of care.
Expertise Areas
- Point-of-care molecular diagnostics
- Host-response biomarker assay development
- Non-invasive sample collection (saliva)
- Clinical development and validation of diagnostics
Key Technologies
- Point-of-care molecular diagnostics
- Saliva-based sampling
- Host-response biomarker panels
- Nucleic-acid/RNA amplification
News & Updates
Company founded in March 2020, pivoted into COVID-19 detection.
Reported cumulative investment of $17 million in company development.
Saliva-based solution used multiple thousands of times and reported comparable performance to other tests.
Company founded in March 2020, pivoted into COVID-19 detection.
Reported cumulative investment of $17 million in company development.
Saliva-based solution used multiple thousands of times and reported comparable performance to other tests.